ASST

ANALYST NOTE: ASST (Strive, Inc.) Date: 2026-06-12 Current Price: $14.85

1. Structural Readiness

State: Context-Only Conservative Entry: — (Awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: — (Not actionable on forming coil alone) Breakout Level: — (Not yet established) Current Price: $14.85 Extension: — ATR Current: 9.4% (Extreme)

Analysis:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None

At this date, there is no named secular thesis driving this name. The investment case is strictly TACTICAL, relying on the quality of the technical setup and the immediate fundamentals of the business rather than a macroeconomic tailwind or a long-term industry shift. The analyst must judge this name solely on the strength of the business fundamentals and the structural readiness of the setup, without inventing a macro narrative. The absence of a named thesis means conviction must be derived entirely from the evidence of operational execution and capital allocation discipline.

3. The Business

Company Overview: Strive, Inc. operates as a structured finance company and institutional asset manager. Following the reverse acquisition of Asset Entities Inc. in September 2025, the company deployed capital to execute a Bitcoin treasury strategy, positioning itself as the first U.S. publicly traded Bitcoin treasury asset management firm.

Business Model & Segments: The company operates two primary segments:

• Asset Management & Treasury: The firm manages assets under management (AUM) and holds a significant Bitcoin reserve.
• AUM: As of March 31, 2026, the company manages over $2.5 billion in AUM (up from $2.4 billion as of December 31, 2025) [E2, E9].
• Bitcoin Holdings: As of March 31, 2026, digital assets totaled approximately $929.4 million (approx. 13,628 BTC). By May 12, 2026, the treasury grew to 15,009 Bitcoin [E3, E4].
• Capital Structure: The company successfully repurchased the remaining balance of long-term notes payable as of May 12, 2026, leaving the company with no short or long-term debt outstanding [E5].
• Dividend Policy: On May 13, 2026, the frequency of regular dividend payments on SATA Stock was changed from monthly to per-Business Day [E8].
• Capital Raise: On January 27, 2026, the company raised approximately $109.3 million in net proceeds via a public follow-on offering of SATA Stock [E7].

• Medical Device Operations (Semler Scientific):
• Revenue Growth: Medical device revenues increased by $1.4 million (100.0%) to $1.4 million for the three months ended March 31, 2026 [E1].
• Product: The subsidiary markets QuantaFlo, a patented and FDA-cleared vascular testing product [E12].
• Distribution: QuantaFlo is placed with healthcare insurance plans, integrated delivery networks, hospitals, and physician groups [E13].

Industry: Financial Services / Asset Management / Medical Technology.

4. Archetype and Conviction

Archetype: Deep Value Recovery / Capital Allocator The company fits the archetype of a Deep Value Recovery combined with a Capital Allocator. The narrative is driven by the successful execution of a capital allocation strategy (Bitcoin accumulation, debt elimination) and the recovery/growth of the underlying medical device business (Semler Scientific).

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. The evidence base is robust, citing specific AUM growth, debt elimination, and revenue doubling in the medical segment.
• Structural Quality: Compromised. While the fundamentals are strong (debt-free, growing AUM), the ATR of 9.4% (Extreme) is a significant negative factor. In the StoryStocks canon, extreme volatility is historically associated with the highest rate of severe losers. This suggests the market is pricing in significant uncertainty or that the stock is in a chaotic consolidation phase.
• Rerating Potential: Moderate. The elimination of debt and the shift to daily dividends could support a rerating, but the extreme volatility currently obscures this.

Valuation Context: The company is trading at $14.85. With $929.4M in digital assets and $2.5B in AUM, the market cap implies a significant premium or discount depending on the valuation of the medical segment and the Bitcoin holdings. However, without a defined earnings multiple or P/B ratio in the evidence, a precise valuation comparison is not possible. The focus remains on the structural setup and the "debt-free" status.

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate:

• A significant reduction in AUM or a sharp decline in the value of the Bitcoin treasury that erodes the balance sheet.
• Failure to maintain the debt-free status (e.g., new borrowings).

What Would Strengthen:

• A confirmed breakout above the forming structure with a reduction in ATR (volatility compression).
• Continued sequential growth in medical device revenue beyond the 100% increase reported.
• Further accumulation of Bitcoin or AUM at a pace that outpaces market expectations.

Gaps in Evidence:

• Profitability Metrics: While the company expects to operate in a "single-digit-million dollar operating loss to single-digit-million dollar operating profit range" for fiscal 2026 [E10], the actual net income or EBITDA for the most recent quarter is not explicitly detailed in the provided evidence.
• Cash Flow: No specific data on operating cash flow or free cash flow is provided.
• Detailed Valuation: No explicit P/E, P/B, or EV/EBITDA multiples are cited in the evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: Debt-free balance sheet as of May 12, 2026; 100% revenue growth in medical segment to $1.4M; AUM growth to $2.5B. Sizing hint: Position size must be minimal due to extreme volatility and unconfirmed setup; treat as a high-risk observation rather than a core holding. Expected path: Management expects to maintain a debt-free status and continue deploying capital; the medical segment is expected to grow; the setup requires a volatility compression and breakout to become actionable. Expected horizon: 3 to 6 months for the structural setup to resolve into a confirmed breakout or invalidation.